ClariVest Asset Management LLC Reduces Stake in Repligen Co. (NASDAQ:RGEN)
ClariVest Asset Management LLC cut its stake in Repligen Co. (NASDAQ:RGEN) by 14.7% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 81,128 shares of the biotechnology company’s stock after selling 14,010 shares during the quarter. ClariVest Asset Management LLC’s holdings in Repligen were worth $4,793,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Bank of Montreal Can lifted its holdings in shares of Repligen by 5.2% during the fourth quarter. Bank of Montreal Can now owns 32,479 shares of the biotechnology company’s stock worth $1,713,000 after purchasing an additional 1,595 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Repligen by 20.8% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,687 shares of the biotechnology company’s stock worth $142,000 after purchasing an additional 462 shares during the period. Oppenheimer Asset Management Inc. acquired a new stake in shares of Repligen during the fourth quarter worth about $110,000. Rhumbline Advisers lifted its holdings in shares of Repligen by 16.5% during the fourth quarter. Rhumbline Advisers now owns 128,308 shares of the biotechnology company’s stock worth $6,767,000 after purchasing an additional 18,132 shares during the period. Finally, SG Americas Securities LLC acquired a new stake in shares of Repligen during the fourth quarter worth about $1,289,000. 85.20% of the stock is currently owned by institutional investors and hedge funds.
A number of equities research analysts recently commented on RGEN shares. Zacks Investment Research raised Repligen from a “hold” rating to a “buy” rating and set a $77.00 target price for the company in a report on Wednesday, May 1st. ValuEngine downgraded Repligen from a “strong-buy” rating to a “buy” rating in a report on Thursday, April 4th. Finally, BidaskClub raised Repligen from a “sell” rating to a “hold” rating in a report on Thursday, May 30th. Three equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $64.20.
Shares of RGEN stock opened at $74.60 on Wednesday. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.18 and a quick ratio of 1.84. The company has a market cap of $3.56 billion, a P/E ratio of 102.19, a P/E/G ratio of 4.64 and a beta of 1.00. Repligen Co. has a twelve month low of $43.02 and a twelve month high of $77.91.
Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Thursday, May 9th. The biotechnology company reported $0.28 earnings per share for the quarter, beating the consensus estimate of $0.26 by $0.02. The company had revenue of $60.63 million during the quarter, compared to analysts’ expectations of $55.09 million. Repligen had a return on equity of 6.35% and a net margin of 10.11%. Repligen’s quarterly revenue was up 35.3% on a year-over-year basis. During the same period last year, the business earned $0.17 earnings per share. As a group, equities analysts predict that Repligen Co. will post 0.93 earnings per share for the current year.
Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.
Featured Article: Dividend Yield
Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Co. (NASDAQ:RGEN).
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.